Efficacy of Continuous Positive Airway Pressure (CPAP) in Patients with Obstructive Sleep Apnea (OSA): A Real-World Study

Dr. Animesh Arya 1, Dr. Seema Arya 2, Dr. Radhika Arya 3

Abstract

Background: Sleep being an essential biological function, has a significant role. The basic structure of sleep consists of non-rapid eye movement (NREM) and rapid eye movement (REM). Obstructive sleep apnea-hypopnea syndrome (OSAHS) is the commonest of sleep-related breathing disorders, which is a chronic disorder characterized by the presence of partial or complete blockage of the upper airway causing reduced (hypopnea) or absent (apnea) airflow during sleep. Continuous positive airway pressure (CPAP) therapy reduces OSA severity, improves both daytime and nocturnal symptoms in particular excessive daytime sleepiness and fatigue.

Objective: Assessment of AHI, Arousal Index, and sleep pattern improvement (N1, N2, N3, and R duration), blood pressure pre and post CPAP therapy and compliance of patients to CPAP therapy over a period of ≥6 months

Methodology: A total 107 polysomnography (PSG) reports of patients who visited the sleep centre from March 2019 to March 2020 were included for the analysis.

Results: Our study reported a significant decrease (p<0.0001) in AHI, Arousal Index, and blood pressure post CPAP therapy in the overall population, both the genders and in all age groups. There was a significant increase in N3, and R (p<0.05) post CPAP therapy in most of the patients, whereas there was a marginal decrease in N1 and N2 post CPAP therapy.

Conclusion: Our results from the real-life clinical setting confirms that CPAP is effective at decreasing AHI, Arousal Index, blood pressure, and adherence to treatment with CPAP reported increased sleep efficiency and improvement in both nocturnal and diurnal symptoms in Indian patients with moderate to severe OSA.

Keywords: Continuous positive airway pressure, obstructive sleep apnea, CPAP, OSA, real-world

Source(s) of Support: No funding was provided.

Conflicting Interest: Nil.

Introduction

Sleep being an essential biological function, has a significant role in learning, memory, emotional regulation, neural development, regulation of cardiovascular and metabolic processes, cellular toxin removal and survival. Good-quality sleep is a major requisite for the maintenance of healthy life.[1]

The basic structure of sleep consists of non-rapid eye movement (NREM) and rapid eye movement (REM). NREM accounts for 75-80 percent of the total time duration of sleep and REM account for the rest. NREM has three stages: Stage 1, 2 and 3. REM is divided into phasic and tonic phases. This whole pattern is called sleep cycle.[2, 3]

As per the International Classification of Sleep Disorders (ICSD), sleep disorders are divided into eight major categories. Sleep-related breathing disorders refers to a spectrum of breathing anomalies rang-
OSA has been recognized as a risk factor for cardiovascular diseases, especially hypertension, stroke, arrhythmias and death. Hypoxia leads to hyperactivity of the sympathetic nervous system; increased oxidative stress and endothelial dysfunction; metabolic and hormonal changes, including activation of the renin-angiotensin-aldosterone system, which accompanies the elevation of BP in these patients.[13,14] Several studies and international guidelines have emphasized OSA as a potentially curable secondary form of hypertension.

OSAHS can be predicted with initial screening by sleep questionnaires such as Stop Bang Questionnaire, Epworth Sleepiness Scale and Berlin Questionnaire, which are commonly applied in clinical practice.[15]

Apnoea/hypopnoea index (AHI) is calculated by the number of obstructive events (apnoeas or hypopnoeas) per hour of sleep and obtained by nocturnal cardiorespiratory events monitoring. AHI is used to define the severity of OSA.[6] Table 1 depicts the categorization of OSA severity using AHI.[16]

<table>
<thead>
<tr>
<th>AHI</th>
<th>OSA Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 5</td>
<td>Normal or primary snoring</td>
</tr>
<tr>
<td>5-15</td>
<td>Mild</td>
</tr>
<tr>
<td>16-30</td>
<td>Moderate</td>
</tr>
<tr>
<td>AHI &gt;30</td>
<td>Severe</td>
</tr>
</tbody>
</table>

Earlier OSA was treated by tracheostomies which had many associated complications. To overcome the obstacles and for significant results, positive airway pressure (PAP) came into existence in the 1980s.[4,11] PAP device is set through a nasal or oronasal mask, overnight or during sleep hours at a set positive pressure. Patients with AHI greater than 15 are recommended for PAP therapy, while patients with AHI greater than 05 and below 15 are advised to use PAP only in the presence of symptoms.[4]

Continuous Positive Airway Pressure (CPAP)

Continuous PAP (CPAP), a gold standard treatment for OSA was invented by Dr Colin Sullivan in 1981.[4,17] American Academy of Sleep Medicine (AASM) has provided guidelines to use CPAP, auto-adjusting PAP (APAP) for the treatment of OSA in adults.[18] The minimum starting CPAP is 4 cm H2O, and the maximum is 15 cm H2O for children and 20 cm H2O for patients greater than 12 years of age.[19] An evidence-based Indian initiative on Obstructive sleep apnoea (INOSA) and consensus guidelines recommend split-night study PSG with an initial Diagnostic study followed by 03 hours of CPAP titration if AHI >40 in patients.[20]
CPAP therapy reduces OSA severity, improves both daytime and nocturnal symptoms in particular excessive daytime sleepiness and fatigue. CPAP has the potential to reduce cardiovascular and mortality events.[18]

A meta-analysis by the American Academy of Sleep Medicine reported substantial improvement in day time sleepiness, quality of life, blood pressure, cardiovascular events in patients with CPAP therapy.[21]

Furthermore, a clinical study by Gulshan Battan et al., to assess the effect of CPAP therapy on the Epworth sleepiness scale (ESS) in Indian patients with moderate and severe OSA enrolled 47 patients. Out of 47 patients, 24 had moderate, and 23 had severe OSA. ESS in both groups improved significantly after one and three months of CPAP therapy.[22]

Further clinical trials by Guilleminault C, Miyachi Y, Gupta A et al. reported a statistically significant reduction in AHI in patients with CPAP therapy.[23-25] Several studies conducted around the world suggests the effectiveness of CPAP in treating OSA.

Since there are a limited number of real-world studies being performed in India therefore, this observational study was carried out to understand the efficacy of CPAP therapy in a real-world population of various ages, genders and comorbidities.

Objectives

The present study was done with the following objectives:

- To determine AHI, Arousal Index, and sleep pattern improvement (N1, N2, N3, and R duration) pre and post CPAP therapy
- To assess the blood pressure improvement pre and post CPAP therapy
- Compliance of patients to CPAP therapy over a period of ≥6 months

Methodology

Study Type: This is an observational, retrospective study based on the polysomnography (PSG) reports from inpatient clinical setting in New Delhi, India. Anonymized and de-identified data were used for analysis. Data de-identified by removing personal identifiers. PSG reports of patients visited the sleep centre from March 2019 to March 2020 were included in the study.

Study Settings: Inpatient (IPD) setting of sleep centre in New Delhi, India

Source of Data: PSG reports of patients with complaints or diagnosis of OSA

Inclusion Criteria:
1. Diagnosis of OSA as per the physician’s discretion.
2. Adult patients were included >18 years of age

Exclusion Criteria:
1. Patients with age <18 years have been excluded from the study.

Data Collection Process:
1. PSG reports based retrospective data was retrieved and included for analysis after assessing for inclusion/exclusion criteria.
2. Information on the patient profiles (age, gender, BMI), AHI values, Arousal Index, Sleep pattern (N1, N2, N3 and R duration) pre and post CPAP, comorbidities, blood pressure were collected and analyzed.

Statistical Analysis

Data analysis was done using Microsoft Excel (2016), and R Studio-3.6.2. Descriptive statistics were presented in the form of categorical and continuous variables. Categorical variables (like age, gender) were expressed as percentages and compared by using exact tests (Chi-square/Fisher exact test). Continuous variables (like age, AHI, Arousal Index) were expressed as means and compared by using T statistics Statistical significance was considered at p<0.05.

Ethical Consideration: Confidentiality of patients has been maintained by de-identifying personal information, and only anonymized data from electronic medical records were used for the analysis.

Results

This study assessed the efficacy of Continuous positive pressure therapy (CPAP) in 107 Obstructive sleep apnea (OSA) patients.

The mean age of the sample population was 54.50 years, and 81.30% were male. The majority (50.46%) of the patients were in the Older adults age group (above 55 years). Sixty-four patients (59.81%) were in the obese category (BMI ≥30). The baseline BMI, AHI, Arousal Index, and Sleep pattern for patients in the study are presented in Table 2.

Assessment of AHI, Arousal Index, and Sleep Pattern Improvement (N1, N2, N3, and R duration) Pre- and Post-CPAP Therapy:

Out of 107 patients, 62 patients had pre and post CPAP AHI values. There was a significant decrease in AHI (p<0.0001) post CPAP therapy in the overall population, both the genders and in all age groups (Table 3-4, Figure 1).

Likewise, out of 107 patients, 36 patients had pre and post CPAP Arousal Index values. There was a significant decrease in Arousal Index (p<0.0001) post
CPAP therapy in the overall population, both the genders and in all age groups (Table 5-6, Figure 2).

Among the sleep characteristics, sleep efficiency improved markedly post CPAP therapy in all the patients. Out of 107 patients, 38 patients were eligible for analysis of pre and post-sleep pattern (N1, N2, N3, and R) duration values. There was a significant increase in N3, and R (p<0.05) post CPAP therapy in most of the patients, whereas there was a marginal decrease in N1 and N2 post CPAP therapy. (Table 7-9, Figure 3).

Evaluation of the Blood Pressure Improvement Pre- and Post CPAP therapy:

Out of 107 patients, 94 patients had pre and post CPAP Blood Pressure values. There was a significant decrease in blood pressure (p<0.0001) post CPAP therapy in the overall population, both the genders and in all age groups (Table 10-11).

Compliance of Patients to CPAP Therapy Over ≥Six Months:

Out of 107 patients, 50 patients (46.72%) had data available for follow-up visit over ≥six months. Among Table 5: Change in Arousal Index (events/ hour) pre- and post-CPAP (overall population)

<table>
<thead>
<tr>
<th>Arousal Index (events/ hour)</th>
<th>Mean (SD)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-CPAP (N=36)</td>
<td>52.71 (23.16)</td>
<td></td>
</tr>
<tr>
<td>Post-CPAP (N=36)</td>
<td>8.61 (4.57)</td>
<td>P &lt; 0.0001</td>
</tr>
</tbody>
</table>

* TST: Total Sleep Time
Gender-Specific Prevalence of OSA at Different Scores of AHI Based on PSG Reports:

Amongst 107 patients majority patients (87, 81.30%) were above 55 years old. Older adults (above 55 years) have a higher prevalence (46.73% with AHI≥5) than Young adults age group (18-35 years with AHI≥5).

Age-Specific Prevalence of OSA at Different Scores of AHI Based on PSG Reports:

Amongst 107 patients majority patients (54, 50.46%) were above 55 years old. Older adults (above 55 years) have a higher prevalence (46.73% with AHI≥5) than Young adults age group (18-35 years with AHI≥5).

Gender-Specific Prevalence of OSA at Different Scores of AHI Based on PSG Reports:

Amongst 107 patients majority patients (87, 81.30%) were above 55 years old. Older adults (above 55 years) have a higher prevalence (46.73% with AHI≥5) than Young adults age group (18-35 years with AHI≥5).

Table 6: Change in Arousal Index (events/ hour) pre- and post-CPAP (gender & age wise)

<table>
<thead>
<tr>
<th>Arousal Index (events/ hour)</th>
<th>Pre-CPAP (N=36)</th>
<th>Post-CPAP (N=36)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>Male (n=30)</td>
<td>51.41</td>
<td>21.34</td>
</tr>
<tr>
<td>Female (n=6)</td>
<td>59.16</td>
<td>28.31</td>
</tr>
<tr>
<td>18-35 (n=2)</td>
<td>20.85</td>
<td>4.25</td>
</tr>
<tr>
<td>36-55 (n=16)</td>
<td>57.21</td>
<td>22.29</td>
</tr>
<tr>
<td>Above 55 (n=18)</td>
<td>52.24</td>
<td>21.64</td>
</tr>
<tr>
<td>P-value</td>
<td>P &lt; 0.0001</td>
<td></td>
</tr>
</tbody>
</table>

Table 7: Change in sleep pattern pre- and post-CPAP (overall population)

<table>
<thead>
<tr>
<th>Sleep Pattern</th>
<th>Pre-CPAP</th>
<th>Post-CPAP</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>Sleep efficiency (%)</td>
<td>79.33</td>
<td>12.79</td>
<td>82.56</td>
</tr>
<tr>
<td>N1 duration (% TST)</td>
<td>3.59</td>
<td>3.30</td>
<td>3.32</td>
</tr>
<tr>
<td>N2 duration (% TST)</td>
<td>65.04</td>
<td>12.64</td>
<td>57.97</td>
</tr>
<tr>
<td>N3 duration (% TST)</td>
<td>17.23</td>
<td>6.74</td>
<td>20.00</td>
</tr>
<tr>
<td>R Duration (% TST)</td>
<td>13.49</td>
<td>7.68</td>
<td>18.57</td>
</tr>
</tbody>
</table>

Table 8: Change in sleep pattern pre- and post-CPAP (gender-wise)

<table>
<thead>
<tr>
<th>Groups</th>
<th>Sleep Pattern</th>
<th>Pre-CPAP (n=38)</th>
<th>Post-CPAP (n=38)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sleep efficiency (%)</td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>Male (n=31)</td>
<td>54.40</td>
<td>0.00</td>
<td>86.70</td>
<td>0.00</td>
</tr>
<tr>
<td>N1 duration (% TST)</td>
<td>4.05</td>
<td>4.32</td>
<td>4.48</td>
<td>6.24</td>
</tr>
<tr>
<td>N2 duration (% TST)</td>
<td>62.82</td>
<td>18.02</td>
<td>57.53</td>
<td>14.58</td>
</tr>
<tr>
<td>N3 duration (% TST)</td>
<td>16.12</td>
<td>7.69</td>
<td>19.58</td>
<td>5.63</td>
</tr>
<tr>
<td>R Duration (% TST)</td>
<td>15.46</td>
<td>10.83</td>
<td>18.16</td>
<td>10.46</td>
</tr>
<tr>
<td>Female (n=7)</td>
<td>Sleep efficiency</td>
<td>78.35</td>
<td>8.84</td>
<td>79.80</td>
</tr>
<tr>
<td>N1 duration (% TST)</td>
<td>3.11</td>
<td>2.20</td>
<td>2.39</td>
<td>1.42</td>
</tr>
<tr>
<td>N2 duration (% TST)</td>
<td>66.64</td>
<td>5.26</td>
<td>59.00</td>
<td>8.06</td>
</tr>
<tr>
<td>N3 duration (% TST)</td>
<td>18.59</td>
<td>5.67</td>
<td>20.09</td>
<td>6.77</td>
</tr>
<tr>
<td>R Duration (% TST)</td>
<td>11.75</td>
<td>3.04</td>
<td>18.50</td>
<td>4.16</td>
</tr>
</tbody>
</table>

Table 9: Change in sleep pattern pre- and post-CPAP (age-wise)

<table>
<thead>
<tr>
<th>Groups</th>
<th>Sleep Pattern</th>
<th>Pre-CPAP (n=38)</th>
<th>Post-CPAP (n=38)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-35 (n=1)</td>
<td>Sleep efficiency</td>
<td>54.40</td>
<td>0.00</td>
<td>86.70</td>
</tr>
<tr>
<td>N1 duration (% TST)</td>
<td>4.05</td>
<td>4.32</td>
<td>4.48</td>
<td>6.24</td>
</tr>
<tr>
<td>N2 duration (% TST)</td>
<td>62.82</td>
<td>18.02</td>
<td>57.53</td>
<td>14.58</td>
</tr>
<tr>
<td>N3 duration (% TST)</td>
<td>16.12</td>
<td>7.69</td>
<td>19.58</td>
<td>5.63</td>
</tr>
<tr>
<td>R Duration (% TST)</td>
<td>15.46</td>
<td>10.83</td>
<td>18.16</td>
<td>10.46</td>
</tr>
<tr>
<td>36-55 (n=17)</td>
<td>Sleep efficiency</td>
<td>78.35</td>
<td>8.84</td>
<td>79.80</td>
</tr>
<tr>
<td>N1 duration (% TST)</td>
<td>3.11</td>
<td>2.20</td>
<td>2.39</td>
<td>1.42</td>
</tr>
<tr>
<td>N2 duration (% TST)</td>
<td>66.64</td>
<td>5.26</td>
<td>59.00</td>
<td>8.06</td>
</tr>
<tr>
<td>N3 duration (% TST)</td>
<td>18.59</td>
<td>5.67</td>
<td>20.09</td>
<td>6.77</td>
</tr>
<tr>
<td>R Duration (% TST)</td>
<td>11.75</td>
<td>3.04</td>
<td>18.50</td>
<td>4.16</td>
</tr>
</tbody>
</table>

Figure 3: Effect of CPAP on sleep pattern (overall population)
were males. Males have a higher prevalence (75.70% with AHI≥5) of OSA in comparison to females (18.69% with AHI≥5).

Existence of Comorbidities with Obstructive Sleep Apnea:

Amongst 107 patients, the most prevalent comorbidity associated with OSA was hypertension (81.82%), followed by obesity (38.18%), and diabetes mellitus (30.91%) (Figure 4).

Discussion

Assessment of AHI, Arousal Index, and Sleep Pattern Improvement (N1, N2, N3, and R duration) Pre- and Post-CPAP Therapy:

Our study reported a significant decrease in AHI (p<0.0001) for 62 patients who had pre and post CPAP AHI values.

A retrospective study by Aaron B Holley et al. enrolled 497 patients and concluded 70.1% of all patients achieved an AHI < 5 using CPAP.[26] Similarly, a systematic review and meta-analysis concluded significant improvement in AHI post CPAP therapy.[27]

In our study, 36 patients who had pre and post CPAP Arousal Index values reported a significant decrease in Arousal Index (p<0.0001) post CPAP therapy.

A network meta-analysis also concluded CPAP as a most efficacious treatment for OSA patients and significantly reduced arousal index.[28] A study by Ryo Tachikawa et al. 29 patients reported mean baseline arousal index (events/h) 34.0 and a decrease (19.4) in arousal index was observed.[30]

Our study reported a significant increase in sleep efficiency, N3, and R duration (p<0.05) post CPAP therapy for 38 patients who had pre and post-sleep pattern.
tern (N1, N2, N3, AND R) duration values available for analysis.

A retrospective study of 45 patients with OSA, the mean age of patients was 52.7 ± 5.6 years. The study reported a significant decrease (P < 0.05) in non-rapid eye movement (NREM) sleep after CPAP therapy.\[31\]

The results of AHI, arousal index and sleep pattern reported in our study was in similar trends to clinical trials and retrospective studies discussed above. Factors like early detection of symptoms of OSA and initiation of CPAP therapy could be the contributory reasons to decrease in AHI, arousal index and sleep pattern values.

**Evaluation of the Blood Pressure Improvement Pre- and Post CPAP Therapy:**

In our study, 94 patients had pre and post CPAP Blood Pressure values. There was a significant decrease in blood pressure (p<0.0001) post CPAP therapy.

Few systematic review and meta-analysis reported CPAP significantly reduce blood pressure in patients with OSA.\[32-33\]

Our results were in concordance with the findings of other clinical studies.

**Age and Gender-Specific Prevalence of OSA at Different Scores of AHI Based on PSG Reports:**

In our study, older adults (above 55 years) and males have a higher prevalence (46.73% and 75.70% with AHI≥5) than young adults age group and females.

A population-based study to assess the prevalence and clinical features of OSA enrolled 305 patients to undergo polysomnography. The study reported 52.1% of males of age group 60-70 years with AHI≥5.\[34\]

Another prevalence study in middle-aged urban Indian men, concluded 19.4% of males of age group 55-65 years with AHI≥5.\[35\]

**Existence of Comorbidities with Obstructive Sleep Apnea:**

In our study, the most prevalent comorbidity associated with OSA was hypertension (81.82%), followed by obesity (38.18%), and diabetes mellitus (30.91%).

Similar findings were reported in the PREDICT trial, enrolled 278 patients, randomized in 1:1 ratio to receive CPAP (n=140) and best supportive care (BSC). The study reported 70% of patients in the CPAP group had hypertension, followed by diabetes.\[36\]

**Study Strengths and Limitations**

Though various clinical studies highlighted the efficacy of CPAP, still there was a dire need for real-world studies to assess the efficacy of CPAP in patients with OSA. This is one of the few real-world studies in Indian OSA patients. The data presented in our study provides useful real-world evidence on the efficacy of CPAP. There are few inherent limitations in the study because of its retrospective observational nature.

**Conclusion**

Our results from the real-life clinical setting support findings from previously conducted clinical trials and other observational studies and confirms that CPAP is effective at decreasing AHI, Arousal Index, blood pressure and adherence to treatment with CPAP reported increased sleep efficiency and improvement in both nocturnal and diurnal symptoms in Indian patients with moderate to severe OSA.

**Acknowledgement:** The authors acknowledge the support provided by Medico-Clinical team (Dr Mannmohan Singh and Parul Lal), data team (Rohit Kumar, Ajendra Pratap Sharma) at Technology HealthCare Big Data Analytics (THB) and the sleep technician (Sultan Alam Khan), in preparing the manuscript.

**References:**


